Related Experiment Video

Updated: Aug 15, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Regression of left ventricular hypertrophy in hypertension--does it reduce cardiovascular risk?

J Braz Nogueira1

  • 1Hospital Santa Maria, Faculdade de Medicina de Lisboa, Lisboa, Portugal. braznogueira@fm.ul.pt

Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology
|October 26, 2005
PubMed

Insights

Reducing left ventricular hypertrophy (LVH) through antihypertensive treatment significantly lowers cardiovascular event rates. This study highlights LVH regression as a key therapeutic target for improved hypertension prognosis.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Clinical Trials

Background:

  • Left ventricular hypertrophy (LVH) is a recognized cardiovascular risk factor.
  • Antihypertensive treatments can reduce left ventricular mass.

Purpose of the Study:

  • To investigate the prognostic impact of LVH regression in patients undergoing antihypertensive treatment.
  • To determine if LVH regression is independently associated with improved cardiovascular outcomes.

Main Methods:

  • Analysis of two LIFE substudies involving prospective antihypertensive treatment.
  • Assessment of LVH regression using electrocardiography (ECG) and echocardiography.
  • Evaluation of cardiovascular event rates in relation to LVH reduction.

Main Results:

  • Greater reduction in LVH correlated with a significant decrease in cardiovascular event rates.
  • This association was independent of the specific antihypertensive treatment used.
  • The blood pressure reduction achieved did not fully explain the observed benefit.

Conclusions:

  • Regression of left ventricular hypertrophy is a crucial therapeutic target in managing hypertension.
  • Achieving LVH regression offers prognostic benefits beyond blood pressure control.
  • These findings support incorporating LVH regression into hypertension treatment strategies for improved patient outcomes.

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...